Could Your Clinical Trial Screener Be Losing Eligible Patients?

Woman experiencing neck pain while looking at her smartphone at home, illustrating potential health concerns and patient symptoms.

A screener question can match the protocol word for word, pass institutional review board (IRB) review and still lose eligible patients. The problem shows up when the question asks for something the patient doesn’t know, such as a subtype the physician never named, a test result the patient never saw or the exact date a medication dose last changed.

When a patient can’t answer a question, the screener can lose that patient in two ways. The patient answers “no” and drops out, or guesses “yes” and fails screening at the clinical research site weeks later. Neither outcome appears in a recruitment report as a screener problem.

‍

What happens when motivated patients reach a question they can’t answer

Antidote’s feasibility tests are short online surveys that put a study’s screening questions in front of people from the target patient population before recruitment begins. In one test for a heart failure with preserved ejection fraction (HFpEF) study, each screening step asked patients to recall something more specific.

Screening step Share of respondents
Reported the umbrella heart failure diagnosis 59.2%
Reported the specific subtype 56.2%
Met a key clinical threshold 44.4%

Interest stayed high among the patients who got through: 87.5% were very interested in taking part. The respondents were motivated. The questions asked for clinical details many patients don’t carry with them.

‍

Three kinds of criteria patients struggle to self-report

Across Antidote’s feasibility tests, protocols that relied on patients recalling these details triggered early self-disqualification, even among motivated respondents.

Criterion type Example from a feasibility test What the test showed
Subtype diagnoses HFpEF study requiring a specific heart failure subtype Fewer respondents could confirm each step beyond the umbrella diagnosis
Prior testing ordered by a physician Lung cancer study asking about biomarker or genomic testing 24.6% reported no clinician-ordered biomarker test, and only 44.6% said they were comfortable asking a doctor about testing options
Treatment history and dose stability Obesity medication-switch study requiring a stable dose over a set period Duration and stability requirements caused most disqualifications, and only 3.1% of respondents qualified

The lung cancer result points to a second issue. When a screener tells patients to “check with your doctor” before answering, fewer than half of the respondents in that test said they were comfortable asking. Patients who aren’t comfortable asking may leave the screener.

‍

How do sponsors test screening questions before launch?

Sponsors test screening questions by running the draft screener with people from the target patient population before recruitment begins. The results show which questions patients can answer on their own and which need confirmation by phone, through medical records or at the clinical research site. Five steps make that test useful.

Flag every criterion that depends on recall.

Review the draft protocol and mark each criterion that asks for a subtype, a test value, a prior test or a date. These are the questions most likely to lose eligible patients.

Write the question in the words patients use.

“Has a doctor told you your heart pumps normally but is stiff?” is easier to answer than a subtype name. Ask for height and weight instead of body mass index (BMI), and offer date ranges instead of exact dates.

Add an “I’m not sure” answer.

A patient who isn’t sure should move forward for confirmation by phone or through medical records, rather than be screened out by the form.

Test the screener with real patient responses.

A short feasibility test shows where patients drop off, which questions draw the most “I’m not sure” answers and which criteria screen out the most respondents.

Decide where each criterion gets confirmed.

Keep criteria that patients answer reliably in the online screener. Move uncertain ones to phone confirmation, and leave test values and imaging to the clinical site.

‍

What to measure for each screener question

Metric What it tells you
Drop-off at the question Whether patients quit when they reach it
“I'm not sure” rate Whether patients have the information the question asks for
Share disqualified by the criterion How much the criterion limits the qualified pool
Very interested among patients who pass Whether the patients who get through want to take part

‍

Frequently Asked Questions

Can patients accurately self-report clinical trial eligibility criteria?

For many criteria, yes: age, a confirmed diagnosis, height and weight. Accuracy drops for subtype diagnoses, numeric thresholds, prior test results and exact treatment dates. Those usually need confirmation by phone, through medical records or at the clinical site.

Should a clinical trial screener include an “I’m not sure” option?

For criteria that depend on recall, an “I’m not sure” option keeps eligible patients from screening themselves out. The answer should send the patient to a confirmation step, not end the screener.

Do screener question changes need IRB review?

Patient-facing screening materials are often reviewed with the recruitment materials. Your compliance team should confirm what your IRB requires before you change screener wording.

Test your screener before recruitment launches

Antidote runs short feasibility tests that put protocol-based screening questions and draft patient-facing messages in front of relevant patient populations before patient recruitment begins. Each test returns a criterion-level breakdown of responses that shows sponsors:

  • Which criteria cause the most self-disqualification
  • Which questions show the most uncertainty or drop-off
  • How interested eligible patients are in taking part
  • Which message variant brings in the most qualified respondents
  • Where wording changes could keep qualified patients in the screener

From those results, Antidote recommends which criteria to keep in the online screener, which to move to contact center clarification and which to leave for clinical confirmation at the site.

‍

Identify Screening Barriers Before Launch: Talk to Antidote About Feasibility Testing
Connect with us
On
November 20, 2026